500 related articles for article (PubMed ID: 27157227)
21. Pulmonary sarcoid-like granulomatosis induced by ipilimumab.
Berthod G; Lazor R; Letovanec I; Romano E; Noirez L; Mazza Stalder J; Speiser DE; Peters S; Michielin O
J Clin Oncol; 2012 Jun; 30(17):e156-9. PubMed ID: 22547608
[No Abstract] [Full Text] [Related]
22. Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma.
Bottlaender L; Breton AL; de Laforcade L; Dijoud F; Thomas L; Dalle S
J Immunother Cancer; 2017 Jul; 5(1):57. PubMed ID: 28716106
[TBL] [Abstract][Full Text] [Related]
23. Sarcoidosis related to checkpoint and BRAF/MEK inhibitors in melanoma.
Rubio-Rivas M; Moreira C; Marcoval J
Autoimmun Rev; 2020 Aug; 19(8):102587. PubMed ID: 32553612
[TBL] [Abstract][Full Text] [Related]
24. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.
Tan I; Malinzak M; Salama AKS
J Immunother Cancer; 2018 Jul; 6(1):77. PubMed ID: 30064495
[TBL] [Abstract][Full Text] [Related]
25. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
Yamauchi I; Sakane Y; Fukuda Y; Fujii T; Taura D; Hirata M; Hirota K; Ueda Y; Kanai Y; Yamashita Y; Kondo E; Sone M; Yasoda A; Inagaki N
Thyroid; 2017 Jul; 27(7):894-901. PubMed ID: 28537531
[TBL] [Abstract][Full Text] [Related]
26. Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: A case-control study.
Cabanié C; Ammari S; Hans S; Pobel C; Laparra A; Danlos FX; Chanson N; Dolidon S; Seban R; Voisin AL; Pautier P; Romano-Martin P; Even C; Baldini C; Besse B; Albiges L; Boutros C; Routier E; Balleyguier C; De Montpreville VT; Champiat S; Massard C; Robert C; Marabelle A; Mateus C; Lambotte O; Le Pavec J; Michot JM
Eur J Cancer; 2021 Oct; 156():46-59. PubMed ID: 34425404
[TBL] [Abstract][Full Text] [Related]
27. Case Report: Sarcoid-Like Reactions and Tertiary Lymphoid Structures Following Dual Checkpoint Inhibition in a Patient with Early-Stage Lung Adenocarcinoma.
Zhao X; Yue D; Qian J; Zhang L; Song J; Zhang B; Zhang C; Sun L; Ma Y; Zhang H; Wang C
Front Immunol; 2022; 13():794217. PubMed ID: 35173719
[TBL] [Abstract][Full Text] [Related]
28. New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment.
Murphy KP; Kennedy MP; Barry JE; O'Regan KN; Power DG
Oncol Res Treat; 2014; 37(6):351-3. PubMed ID: 24903767
[TBL] [Abstract][Full Text] [Related]
29. Sarcoid-like Granulomatous Intraocular Inflammation Caused by Vemurafenib Treatment for Metastatic Melanoma.
Eser Öztürk H; Süllü Y
Turk J Ophthalmol; 2020 Mar; 50(1):50-52. PubMed ID: 32167264
[TBL] [Abstract][Full Text] [Related]
30. Atezolizumab-induced sarcoid-like granulomatous reaction in a patient with urothelial cell carcinoma.
Mitchell MA; Hogan K; Amjadi K
Immunotherapy; 2018 Oct; 10(14):1189-1192. PubMed ID: 30326785
[TBL] [Abstract][Full Text] [Related]
31. Granulomatous Reaction in a Patient With Metastatic Melanoma Treated With Ipilimumab: First Case Reported With Isolated Cutaneous Findings.
Cervantes J; Rosen A; Dehesa L; Dickinson G; Alonso-Llamazares J
Actas Dermosifiliogr (Engl Ed); 2019; 110(1):43-49. PubMed ID: 30389125
[TBL] [Abstract][Full Text] [Related]
32. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab.
Gauci ML; Baroudjian B; Laly P; Madelaine I; Da Meda L; Vercellino L; Bagot M; Lioté F; Pages C; Lebbé C
Semin Arthritis Rheum; 2017 Oct; 47(2):281-287. PubMed ID: 28438383
[TBL] [Abstract][Full Text] [Related]
33. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Weber JS; D'Angelo SP; Minor D; Hodi FS; Gutzmer R; Neyns B; Hoeller C; Khushalani NI; Miller WH; Lao CD; Linette GP; Thomas L; Lorigan P; Grossmann KF; Hassel JC; Maio M; Sznol M; Ascierto PA; Mohr P; Chmielowski B; Bryce A; Svane IM; Grob JJ; Krackhardt AM; Horak C; Lambert A; Yang AS; Larkin J
Lancet Oncol; 2015 Apr; 16(4):375-84. PubMed ID: 25795410
[TBL] [Abstract][Full Text] [Related]
34. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
[TBL] [Abstract][Full Text] [Related]
35. Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation.
Chanson N; Ramos-Casals M; Pundole X; Suijkerbuijk K; José de Barros E Silva M; Lidar M; Benesova K; Leipe J; Acar-Denizli N; Pradère P; Michot JM; Voisin AL; Suárez-Almazor ME; Radstake TRD; Fernandes Moça Trevisani V; Schulze-Koops H; Melin A; Robert C; Mariette X; Baughman RP; Lambotte O; ; ; ; ; ;
Eur J Cancer; 2021 Nov; 158():208-216. PubMed ID: 34452793
[TBL] [Abstract][Full Text] [Related]
36. Safety of pembrolizumab for the treatment of melanoma.
Martin-Liberal J; Kordbacheh T; Larkin J
Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979
[TBL] [Abstract][Full Text] [Related]
37. Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature.
Reuss JE; Kunk PR; Stowman AM; Gru AA; Slingluff CL; Gaughan EM
J Immunother Cancer; 2016; 4():94. PubMed ID: 28031822
[TBL] [Abstract][Full Text] [Related]
38. Granulomatous/sarcoid-like reactions in the setting of programmed cell death-1 inhibition: a potential mimic of disease recurrence.
Hiraki T; Hatanaka M; Arimura A; Kawahira H; Kirishima M; Kitazono I; Horinouchi M; Higashi M; Kanekura T; Tanimoto A
J Cutan Pathol; 2020 Feb; 47(2):154-160. PubMed ID: 31437317
[TBL] [Abstract][Full Text] [Related]
39. Sarcoidosis in Patients Treated with Vemurafenib for Metastatic Melanoma: A Paradoxical Autoimmune Activation.
Lheure C; Kramkimel N; Franck N; Laurent-Roussel S; Carlotti A; Queant A; Goldwasser F; Avril MF; Dupin N
Dermatology; 2015; 231(4):378-84. PubMed ID: 26452227
[TBL] [Abstract][Full Text] [Related]
40. Complete response to anti-PD-1 nivolumab in massive skin metastasis from melanoma: efficacy and tolerability in an elderly patient.
Sponghini A; Patrucco F; Giorgione R; Farinelli P; Zottarelli F; Rondonotti D; Savoia P
Anticancer Drugs; 2017 Aug; 28(7):808-810. PubMed ID: 28489616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
